Cite
HARVARD Citation
Berton-Rigaud, D. et al. (n.d.). 268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101). Journal for immunotherapy of cancer. pp. A164-A165. [Online].